Abbott Laboratories (NYSE:ABT) has moved forward to announce the CE Mark of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, which as a matter of fact has been put up to make it much easier for the different physicians to effectively atrial fibrillation (AF), a situation in which the upper chambers of the heart beat in an unusual will and fast rate.
When merged with Abbott’s EnSite Precision™ cardiac mapping system, the wide range of physicians become well-placed to actually get to utilize the dual impedance and magnetic technologies to in a major way assist model the heart in a much more precise way.
The other thing that is worth mentioning at this point in time is that fact that the integrated system will move quite a long way towards helping physicians get to determine the exact areas where they needed to go ahead and as a matter of fact apply the optimal contact force (pressure) when coming up with a lesion during that instance of a cardiac ablationin an effort to try and alter the heart rhythm abnormality.
The Sensor Enabled technology is such that it allows physicians to come up with a more detailed heart model during ablation procedures and that is by far better performing that the ordinary catheter lacking a sensor.
The top medical experts insist that Arrhythmias usually develops during those instances when the various electrical signals regulating the heart rhythms get disrupted or are tampered with and as a result causing the heart to beat in an irregular manner.
The same experts have gone ahead to say that any patient with AF suffers a much more increased risk for stroke and the best explanation would be that the rapid heartbeat causes the blood to pool in the heart, after which there is the formation of close that eventually move to the brain.
The medical director of Abbott’s electrophysiology business, Srijoy Mahapatra in addressing a press conference said, “The goal in developing the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ was to provide the most innovative solution for treating atrial fibrillation and lead the way in clinical outcomes for patients with cardiac arrhythmias – even during long and complex ablation procedures,”
We are looking forward to a lot of good things, but time will tell.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
A new field of medicine needs attentionhttps://journaltranscript.com
Here are the reasons to invest in CMXC
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why